Japan-USA HARMONEE研究:Combo支架与依维莫司洗脱支架随机对照主要结果
HARMONEE随机注册试验将572例稳定PCI患者1:1分配至Combo支架或依维莫司洗脱支架(EES),1年靶血管失败(TVF)Combo组7.0% vs EES组4.2%,差异2.8%(95%CI -1.0%, 6.5%),满足非劣效假设(P=0.02);OCT显示Combo组1年支架小梁覆盖率91.3% vs 74.8%(P<0.001),作为EPC捕获活性的替代指标更优。
要点
- Combo支架1年TVF非劣于EES,差异2.8%(95%CI -1.0%, 6.5%),非劣效P=0.02。
- OCT 1年支架小梁覆盖率Combo 91.3% vs EES 74.8%,P<0.001。
- 两组均无心源性死亡,EES组发生1例支架血栓。
核心结论
- Combo支架对比EES在1年TVF和晚期管腔丢失上达到非劣效,且OCT支架小梁组织覆盖率更优,提示EPC捕获技术活性。
研究设计与样本
- 随机、多中心、 pivotal注册试验(HARMONEE,NCT02073565),572例临床稳定PCI患者随机1:1接受Combo或EES支架,共675处冠状动脉病变。
主要发现
- 1年TVF:Combo组7.0%(20/287) vs EES组4.2%(12/285),差异2.8%(95%CI -1.0%, 6.5%),非劣效P=0.02。
- OCT 1年支架小梁覆盖率:Combo 91.3%(95%CI 88.7%, 93.8%) vs EES 74.8%(95%CI 70.0%, 79.6%),P<0.001;均匀组织比例分别为81.2% vs 68.8%。
- 无心脏死亡,EES组出现1例支架血栓;定量冠脉造影晚期管腔丢失Combo与EES等效。
关键数值与推荐
- 主要临床终点为1年TVF非劣效;主要机制终点为OCT支架小梁覆盖率优效。
临床怎么用
- 对于接受PCI的缺血性冠心病及非ST段抬高型急性冠脉综合征患者,Combo支架可作为EES的替代选择,其EPC捕获特性可能促进支架愈合。
局限性
- OCT亚组仅纳入前140例患者,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (HARMONEE) (NCT02073565) was a randomized pivotal registration trial of the Combo stent, which combined sirolimus and an abluminal bioabsorbable polymer with a novel endoluminal anti-CD34+ antibody coating designed to capture endothelial progenitor cells (EPC) and promote percutaneous coronary intervention (PCI) site healing. METHODS AND RESULTS: Clinically stabilized PCI subjects were randomized 1:1 to receive Combo or everolimus-eluting stents (EES). Between February 2014 and June 2016, 572 subjects with 675 coronary lesions underwent 1-year angiography and fractional flow reserve, with optical coherence tomography (OCT) in the first 140 patients. The primary clinical endpoint was non-inferior 1-year target vessel failure (TVF). The primary mechanistic endpoint of EPC capture activity was superior strut coverage by OCT. Target vessel failure occurred in 7.0% Combo (20/287) vs. 4.2% EES (12/285), a 2.8% [95% confidence interval (95% CI) -1.0%, 6.5%] difference, meeting the non-inferiority hypothesis (P = 0.02). There were no cardiac deaths, with one stent thrombosis observed in the EES group. Quantitative coronary angiography late loss with Combo was equivalent to EES. Optical coherence tomography strut coverage at 1 year was superior with Combo vs. EES [91.3% (95% CI 88.7%, 93.8%) vs. 74.8% (95% CI 70.0%, 79.6%), P < 0.001], with homogeneous tissue in 81.2% vs. 68.8%, respectively. CONCLUSION: Combo stent demonstrated non-inferior 1-year TVF and late loss in a randomized comparison to EES, with superior strut-based tissue coverage by OCT as a surrogate of EPC capture technology activity.
引用
- Saito S, Krucoff MW, Nakamura S, et al. Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome. Eur Heart J. 2018. PMID: 29931092. doi:10.1093/eurheartj/ehy275
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。